Tocilizumab for systemic sclerosis: implications for future trials

The Lancet

Volumn 387, Issue 10038, 2016, Pages 2580-2581

  Distler, Oliver ^a   Distler, Jörg H W ^b  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; TOCILIZUMAB; MONOCLONAL ANTIBODY;

CONTROLLED CLINICAL TRIAL (TOPIC); DISEASE MARKER; DRUG BLOOD LEVEL; FINGER ULCER; FORCED VITAL CAPACITY; GENE EXPRESSION; GENOME-WIDE ASSOCIATION STUDY; HUMAN; INFECTION RISK; MACROPHAGE ACTIVATION; NOTE; OSTEOMYELITIS; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROXIMAL INTERPHALANGEAL JOINT; RHEUMATIC DISEASE; SKIN DISEASE; SKIN FIBROSIS; SYSTEMIC SCLEROSIS; TISSUE INJURY; FEMALE; MALE; SCLERODERMA, SYSTEMIC;

ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; HUMANS; MALE; SCLERODERMA, SYSTEMIC;

EID: 84965056931     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(16)00622-X     Document Type: Note

References (12)

1. 1 Kowal-Bielecka, O, Landewe, R, Avouac, J, et al. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis 68 (2009), 620–628.
2. 2 Distler, O, Cozzio, A, Systemic sclerosis and localized scleroderma-current concepts and novel targets for therapy. Semin Immunopathol 38 (2016), 87–95.
3. 3 Ramming, A, Dees, C, Distler, JH, From pathogenesis to therapy—perspective on treatment strategies in fibrotic diseases. Pharmacol Res 100 (2015), 93–100.
4. 4 Khanna, D, Denton, CP, Jahreis, A, et al. Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial. Lancet, 2016 published online May 5. http://dx.doi.org/10.1016/S0140-6736(16)00232-4.
5. 5 Maurer, B, Graf, N, Michel, BA, et al. Prediction of worsening of skin fibrosis in patients with diffuse cutaneous systemic sclerosis using the EUSTAR database. Ann Rheum Dis 74 (2015), 1124–1131.
6. 6 Prasse, A, Pechkovsky, DV, Toews, GB, et al. CCL18 as an indicator of pulmonary fibrotic activity in idiopathic interstitial pneumonias and systemic sclerosis. Arthritis Rheum 56 (2007), 1685–1693.
7. 7 Braga, TT, Agudelo, JS, Camara, NO, Macrophages during the fibrotic process: M2 as friend and foe. Front Immunol, 6, 2015, 602.
8. 8 Wynn, TA, Chawla, A, Pollard, JW, Macrophage biology in development, homeostasis and disease. Nature 496 (2013), 445–455.
9. 9 Pendergrass, SA, Lemaire, R, Francis, IP, Mahoney, JM, Lafyatis, R, Whitfield, ML, Intrinsic gene expression subsets of diffuse cutaneous systemic sclerosis are stable in serial skin biopsies. J Invest Dermatol 132 (2012), 1363–1373.
10. 10 Dobrota, R, Mihai, C, Distler, O, Personalized medicine in systemic sclerosis: facts and promises. Curr Rheumatol Rep, 16, 2014, 425.
11. 11 Maurer, B, Distler, A, Dees, C, et al. Levels of target activation predict antifibrotic responses to tyrosine kinase inhibitors. Ann Rheum Dis 72 (2013), 2039–2046.
12. 12 Wynn, TA, Barron, L, Macrophages: master regulators of inflammation and fibrosis. Semin Liver Dis 30 (2010), 245–257.